Alzheimer' s disease markers

Patent Pending The Alzheimer's disease biomarkers are neurochemical indicators used to assess the risk or presence of the disease. The biomarkers can be used to diagnose Alzheimer's disease (AD) in a very early stage, but they also provide objective and reliable measures of disease progress. It is imperative to diagnose AD disease as soon as possible, because neuropathologic changes of AD precede the symptoms by years. It is well known how beta amyloid (Aβ) is a good indicator of AD disease, which has facilitated doctors to accurately pre-diagnose cases of AD disease. When Aβ peptide is released by proteolytic cleavage of amyloid precursor protein,[1] some Aβ peptides that are solubilized are detected in CSF and blood plasma which makes AB peptides a promising candidate for biological markers.